Loading...
Loading...
CUE| Name | Value |
|---|---|
| Revenues | 2.7M |
| Cost of Revenue | 0.9M |
| Gross Profit | 1.8M |
| Operating Expense | 12.2M |
| Operating I/L | -10.4M |
| Other Income/Expense | 0.2M |
| Interest Income | 0.4M |
| Pretax | -10.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -10.2M |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development of biologic drugs for the selective modulation of the human immune system. Its lead drug candidate, CUE-101, is in Phase 1b clinical trial and is designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company also offers other fusion protein biologics, such as CUE-102 and CUE-103, targeting various cancers and chronic infectious diseases. Additionally, Cue Biopharma has collaboration agreements with Merck Sharp & Dohme Corp., LG Chem Life Sciences, and Albert Einstein College of Medicine for the research and development of its proprietary biologics targeting autoimmune diseases and oncology.
